Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Degenerative disc" patented technology

Intervertebral disc repair, methods and devices therefor

The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc.
Owner:VELOCITY FINANCIAL GRP INC ITS SUCCESSORS & ASSIGNS

Degenerative disc regeneration techniques

InactiveUS20070093905A1Reducing TNF-a productionLowering IL-1 productionSpinal implantsTissue regenerationIntervertebral diskDegenerative disc disease
In the repair / regenerate of the intervertebral disc, all or a portion of the nucleus pulposus or annulus fibrosus is excised and treated for reinsertion into the disc or adjacent or alternate level disc. Alternatively certain bioactive agents may be injected into the degenerative disc without excising disc material.
Owner:DEPUY SPINE INC (US) +1

Mixed porous structure interbody fusion cage and preparation method thereof

Disclosed are a mixed porous structure interbody fusion cage and a preparation method thereof. The interbody fusion cage comprises a porous metal support and porous structure filling bodies, the porous metal support is a three-dimensional net-shaped structure, a plurality of holes are arranged in the porous metal support, and the porous structure filling bodies are fully filled in the holes. The preparation method includes steps that the metal rapid forming technology is directly combined with the freeze drying technology, the porous metal support is manufactured via a structural design and the direct metal rapid forming technology, then uniformly mixed polymer gel or polymer / biological ceramic compound gel is poured in the porous metal support to realize freeze treatment, so that the porous structure filling bodies with the micropore feature are formed after freeze drying, and the mixed porous structure interbody fusion cage is obtained. Mechanical compatibility is good, contact area between the mixed porous structure interbody fusion cage and natural centrum is further increased, instant stability is good, fusion rate is improved, and the mixed porous structure interbody fusion cage and the preparation method thereof can be used for treating clinical degenerative disc diseases.
Owner:SHANGHAI JIAO TONG UNIV

Injectible bodily prosthetics employing methacrylic copolymer gels

The present invention provides novel block copolymers as structural supplements for injectible bodily prosthetics employed in medical or cosmetic procedures. The invention also includes the use of such block copolymers as nucleus pulposus replacement materials for the treatment of degenerative disc disorders and spinal injuries. The copolymers are constructed by polymerization of a tertiary amine methacrylate with either a (poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) polymer, such as the commercially available Pluronic® polymers, or a poly(ethylene glycol) methyl ether polymer.
Owner:IOWA STATE UNIV RES FOUND

Implants for treatment of symptomatic or degenerated intervertebral discs

Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also comprise one or more binders. The device can be an elongate solid body having a tapered or rounded insertion end. Alternatively, the device can include a plurality of particles. For devices containing multiple active agents, the configuration of the device be chosen to provide for the sequential or simultaneous release of each of the active agents. The elongate solid body can include a sheath comprising a first active agent and a core comprising a second active agent.
Owner:WARSAW ORTHOPEDIC INC

Methods for the treatment of degenerative disc diseases by human birth tissue material composition

Methods for treating degenerative disc disease by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into at least one intervertebral disc or intervertebral space in need of treatment.
Owner:BIODLOGICS

Predictive intervertebral disc degeneration detection engine

Systems, methods and computer program products for facilitating the prognosis of degenerative disc disorder (DDD) are provided. In one aspect, intervertebral disc loss is predicted based on receiving image data comprising one or more images of the human spine; segmenting, using a processor, disc regions of said one or more images; generating, using the processor, individual biomarkers based on texture features of said segmented disc regions; generating, using the processor, a predicting intervertebral disc loss based in part on the prognostic marker generated from the individual biomarkers.
Owner:GENERAL ELECTRIC CO

Spinal disk regenerative composition and method of manufacture and use

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).
Owner:VIVEX BIOLOGICS GRP INC

Preparation for treating degenerative disc diseases and preparation method thereof

The invention relates to the technical field of lumbar intervertebral disc medical treatment, in particular to a preparation for treating degenerative disc diseases and a preparation method. The preparation for treating the degenerative disc diseases comprises mesenchymal stem cells, and the mesenchymal stem cells are induced and cultured by a conditional culture medium of chondrocytes, so that the differentiation of the mesenchymal stem cells is facilitated; and the mesenchymal stem cells are wrapped with hydrogel, and the survival rate and activity of the mesenchymal stem cells in the body are enhanced. The invention also provides a heat preservation injector used for the preparation for treating degenerative disc diseases, and the tube wall of the heat preservation injector is filled with a heat preservation material, so that the temperature of contents is ensured, the activity of cells is favorably maintained, and the stress reaction of an organism is reduced.
Owner:中国人民解放军联勤保障部队第九二〇医院

Alpha adreneric receptor agonists for treatment of degenerative disc disease

Effective treatments of pain and / or inflammation from degenerative disc disease and / or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and / or facet joint, one can reduce, prevent or treat pain and / or inflammation caused by the degenerative disc disease and / or facet joint.
Owner:WARSAW ORTHOPEDIC INC

Novel peptide and use thereof

The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1, a variant thereof and a pharmaceutically acceptable salt thereof.A novel peptide of the present invention, a variant thereof and a pharmaceutically acceptable salt thereof are effective for treating and / or preventing degenerative disc diseases, treating body organ fibrosis, treating cancer and / or treating glomerulosclerosis, and are effective for the inhibition of TGF-beta1 signaling.
Owner:ENSOL BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products